{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:28:58Z","timestamp":1793946538175,"version":"4.8.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.critrevonc.2026.105494","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T15:19:42Z","timestamp":1784906382000},"page":"105494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A spotlight on PTEN alterations in prostate cancer: A narrative review"],"prefix":"10.1016","volume":"226","author":[{"given":"Domiziana","family":"Alaimo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Di Costanzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Oltrecolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Oing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Rescigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.critrevonc.2026.105494_bib1","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.cell.2015.10.025","article-title":"The Molecular Taxonomy of Primary Prostate Cancer","volume":"163","author":"Abeshouse","year":"2015","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105494_bib2","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1158\/0008-5472.CAN-08-3667","article-title":"Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer","volume":"69","author":"Attard","year":"2009","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105494_bib3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/ng.2279","article-title":"Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer","volume":"44","author":"Barbieri","year":"2012","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105494_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/cancers11040435","article-title":"PTEN as a Prognostic\/Predictive Biomarker in Cancer: An Unfulfilled Promise","volume":"11","author":"Bazzichetto","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105494_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1593\/neo.131704","article-title":"SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts","volume":"16","author":"Blattner","year":"2014","journal-title":"Neoplasia"},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105494_bib6","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1158\/1078-0432.CCR-18-0937","article-title":"SPOP-Mutated\/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity","volume":"24","author":"Boysen","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105494_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102992","article-title":"Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis","volume":"151","author":"Buonerba","year":"2020","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105494_bib8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105494_bib9","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1101\/gad.1395006","article-title":"The deficiency of Akt1 is sufficient to suppress tumor development in Pten +\/\u2212 mice","volume":"20","author":"Chen","year":"2006","journal-title":"Genes. & Dev."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105494_bib10","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.eururo.2022.05.019","article-title":"Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial","volume":"82","author":"Crabb","year":"2022","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105494_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.20.01576","article-title":"Pan-AKT Inhibitor Capivasertib With Docetaxel and Prednisolone in Metastatic Castration-Resistant Prostate Cancer: A Randomized, Placebo-Controlled Phase II Trial (ProCAID","volume":"39","author":"Crabb","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"6_","key":"10.1016\/j.critrevonc.2026.105494_bib12","article-title":"CAPItello-280: A phase III study of capivasertib and docetaxel versus placebo and docetaxel in metastatic castration-resistant prostate cancer","volume":"41","author":"Crabb","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105494_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/cancers9040034","article-title":"AR Signaling and the PI3K Pathway in Prostate Cancer","volume":"9","author":"Crumbaker","year":"2017","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105494_bib14","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1038\/bjc.2013.248","article-title":"Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer","volume":"108","author":"Cuzick","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105494_bib15","doi-asserted-by":"crossref","first-page":"vi243","DOI":"10.1093\/annonc\/mdw372.02","article-title":"PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC","volume":"27","author":"de Bono","year":"2016","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105494_bib16","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105494_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.eururo.2024.12.015","article-title":"Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial","volume":"87","author":"de Bono","year":"2025","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105494_bib18","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/1535-7163.MCT-23-0724","article-title":"Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness","volume":"25","author":"Di Costanzo","year":"2026","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105494_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.3390\/immuno4040028","article-title":"Mechanisms of Immune Evasion in PTEN Loss Prostate Cancer","volume":"4","author":"Esteban-Villarrubia","year":"2024","journal-title":"Immuno"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105494_bib20","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.eururo.2014.10.027","article-title":"PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate","volume":"67","author":"Ferraldeschi","year":"2015","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105494_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2026","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105494_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.semcancer.2017.04.014","article-title":"PDK1: At the crossroad of cancer signaling pathways","volume":"48","author":"Gagliardi","year":"2018","journal-title":"Semin. Cancer Biol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105494_bib23","doi-asserted-by":"crossref","first-page":"7929","DOI":"10.1158\/0008-5472.CAN-06-1637","article-title":"Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice","volume":"66","author":"Gao","year":"2006","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105494_bib24","doi-asserted-by":"crossref","first-page":"5717","DOI":"10.1016\/j.cell.2025.07.042","article-title":"Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers","volume":"188","author":"Grist","year":"2025","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105494_bib25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ccr.2008.12.017","article-title":"mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice","volume":"15","author":"Guertin","year":"2009","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105494_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.eururo.2018.11.045","article-title":"Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer","volume":"76","author":"Hamid","year":"2019","journal-title":"Eur. Urol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105494_bib27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nrurol.2018.9","article-title":"Clinical implications of PTEN loss in prostate cancer","volume":"15","author":"Jamaspishvili","year":"2018","journal-title":"Nat. Rev. Urol."},{"issue":"10437","key":"10.1016\/j.critrevonc.2026.105494_bib28","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet Commission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.critrevonc.2026.105494_bib29","doi-asserted-by":"crossref","first-page":"6083","DOI":"10.1158\/0008-5472.CAN-06-4202","article-title":"Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development","volume":"67","author":"Jiao","year":"2007","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105494_bib30","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.euo.2023.12.012","article-title":"Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients","volume":"7","author":"Jim\u00e9nez","year":"2024","journal-title":"Eur. Urol. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105494_bib31","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.annonc.2020.01.074","article-title":"A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer","volume":"31","author":"Kolinsky","year":"2020","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105494_bib32","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/modpathol.2014.70","article-title":"Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer","volume":"27","author":"Krohn","year":"2014","journal-title":"Mod. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105494_bib33","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","article-title":"The functions and regulation of the PTEN tumour suppressor: new modes and prospects","volume":"19","author":"Lee","year":"2018","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.critrevonc.2026.105494_bib34","first-page":"18","article-title":"Post-Translational Modification of PTEN Protein: Quantity and Activity","author":"Li","year":"2024","journal-title":"Oncol. Rev."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105494_bib35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nrd2926","article-title":"Targeting the phosphoinositide 3-kinase pathway in cancer","volume":"8","author":"Liu","year":"2009","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.critrevonc.2026.105494_bib36","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.14694\/EdBook_AM.2014.34.e197","article-title":"Molecular Characterization and Clinical Utility of Circulating Tumor Cells in the Treatment of Prostate Cancer","volume":"34","author":"Lorente","year":"2014","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105494_bib37","doi-asserted-by":"crossref","first-page":"6563","DOI":"10.1158\/1078-0432.CCR-11-1244","article-title":"PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients","volume":"17","author":"Lotan","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"39","key":"10.1016\/j.critrevonc.2026.105494_bib38","doi-asserted-by":"crossref","first-page":"65566","DOI":"10.18632\/oncotarget.19217","article-title":"PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort","volume":"8","author":"Lotan","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105494_bib39","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","article-title":"AKT\/PKB Signaling: Navigating the Network","volume":"169","author":"Manning","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105494_bib40","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.eururo.2014.08.053","article-title":"High Efficacy of Combination Therapy Using PI3K\/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models","volume":"67","author":"Marques","year":"2015","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105494_bib41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.clgc.2023.01.001","article-title":"Safety Profile of Ipatasertib Plus Abiraterone vs Placebo Plus Abiraterone in Metastatic Castration-resistant Prostate Cancer","volume":"21","author":"Matsubara","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105494_bib42","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41388-023-02875-4","article-title":"PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression","volume":"43","author":"Miller","year":"2024","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105494_bib43","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/2159-8290.CD-12-0222","article-title":"Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer","volume":"2","author":"Miyamoto","year":"2012","journal-title":"Cancer Discov."},{"issue":"55","key":"10.1016\/j.critrevonc.2026.105494_bib44","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000189","article-title":"Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis","volume":"2","author":"Nardella","year":"2009","journal-title":"Sci. Signal."},{"key":"10.1016\/j.critrevonc.2026.105494_bib45","doi-asserted-by":"crossref","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform \u03b1-specific PI3K inhibitors","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105494_bib46","first-page":"3","article-title":"Genomic Rearrangements of PTEN in Prostate Cancer","author":"Phin","year":"2013","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105494_bib47","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00428-016-1904-2","article-title":"prostate cancer needle biopsies, detections of PTEN loss by fluorescence in situ hybridization (FISH) and by immunohistochemistry (IHC) are concordant and show consistent association with upgrading","volume":"468","author":"Pican\u00e7o-Albuquerque","year":"2016","journal-title":"Virchows Arch."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105494_bib48","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4161\/cc.4.7.1795","article-title":"PTEN Loss Inhibits CHK1 to Cause Double Stranded-DNA Breaks in Cells","volume":"4","author":"Puc","year":"2005","journal-title":"Cell. Cycle"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105494_bib49","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/bjc.2015.332","article-title":"PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients","volume":"113","author":"Punnoose","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105494_bib50","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.5096","article-title":"Real-world patient (pt) characteristics, treatment patterns, and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC): Insights by PTEN status","author":"Rathkopf","year":"2025","journal-title":"J. Clin. Oncol. 43(16_suppl) 50965096"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105494_bib51","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/modpathol.2011.207","article-title":"Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer","volume":"25","author":"Reid","year":"2012","journal-title":"Mod. Pathol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105494_bib52","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.euo.2018.02.006","article-title":"Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers","volume":"1","author":"Rescigno","year":"2018","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105494_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114103","article-title":"Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial","volume":"205","author":"Rescigno","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105494_bib54","doi-asserted-by":"crossref","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-17-0972","article-title":"Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical Qualification","volume":"23","author":"Seed","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"7_","key":"10.1016\/j.critrevonc.2026.105494_bib55","article-title":"Measurement science of the androgen receptor splice variant-7 protein in primary and castration-resistant prostate cancer tissue","volume":"37","author":"Sharp","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105494_bib56","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105494_bib57","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/nrm3330","article-title":"The functions and regulation of the PTEN tumour suppressor","volume":"13","author":"Song","year":"2012","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"10295","key":"10.1016\/j.critrevonc.2026.105494_bib58","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105494_bib59","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105494_bib60","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0228","article-title":"The androgen-thyroid hormone crosstalk in prostate cancer and the clinical implications","volume":"12","author":"Torabinejad","year":"2023","journal-title":"Eur. Thyroid. J."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105494_bib61","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105494_bib62","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1042\/CS20160026","article-title":"Prostate cancer, PI3K, PTEN and prognosis","volume":"131","author":"Wise","year":"2017","journal-title":"Clin. Sci."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105494_bib63","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-019-0954-x","article-title":"Targeting PI3K in cancer: mechanisms and advances in clinical trials","volume":"18","author":"Yang","year":"2019","journal-title":"Mol. Cancer"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826003811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:45:52Z","timestamp":1793943952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826003811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":63,"alternative-id":["S1040842826003811"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105494","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A spotlight on PTEN alterations in prostate cancer: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105494","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105494"}}